Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Combined with Sintilimab and Chemoradiotherapy for LARC
NCT06931808Phase 4Enrolling by invitation
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of sintilimab in rectal cancer, sponsored by First Affiliated Hospital of Ningbo University. Started Mar 2025; status: enrolling by invitation.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06931808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931808.